Show simple item record

dc.contributor.advisorPRASAD, BHAGWAT
dc.contributor.authorCHAPA, REVATHI
dc.date.accessioned2019-10-15T23:01:01Z
dc.date.submitted2019
dc.identifier.otherCHAPA_washington_0250O_20740.pdf
dc.identifier.urihttp://hdl.handle.net/1773/44881
dc.descriptionThesis (Master's)--University of Washington, 2019
dc.description.abstractFurosemide is a widely used diuretic for treating excessive fluid accumulation caused by disease conditions like heart failure and liver cirrhosis. Furosemide exhibits variable pharmacokinetics (PK) with bioavailability ranging from 10-100%, which is attributed to its low solubility and low permeability. Furosemide also shows moderate negative food effect despite of its higher solubility in fed-condition. To explain these clinical observations, we hypothesized that transporter mediated permeability plays a significant role in variable absorption, food effect and elimination of furosemide. To test this, we i) characterized the role of intestinal efflux transporters in furosemide absorption including food-effect and ii) predicted the contribution of renal uptake and efflux transporters on its disposition by using a proteomics-informed mechanistic physiologically based pharmacokinetic (PBPK) modeling. Our in vitro results confirmed that furosemide is a substrate of various intestinal transporters, i.e., BCRP, MRP4 and OATP2B1. The PBPK model suggests that fasting condition leads to saturation of BCRP because of the faster gastric emptying. On the other hand, delayed gastric emptying allows efficient BCRP mediated furosemide efflux in fed condition, hence explains the negative food effect. The study could be further extended to test the effect of BCRP, MRP4 and OATP2B1 genetic polymorphisms or drug-interactions on absorption, disposition, efficacy and toxicity of furosemide. Further, as furosemide has been proposed as a probe substrate of renal organic anion transporters (OATs) for assessing clinical drug-drug interactions (DDIs) during drug development, the confounding effects of intestinal transporters on furosemide PK should be considered while interpreting such clinical transporter DDI studies.
dc.format.mimetypeapplication/pdf
dc.language.isoen_US
dc.rightsnone
dc.subject
dc.subjectPharmaceutical sciences
dc.subject.otherPharmaceutics
dc.titleInvestigating the role of drug transporters in furosemide absorption, food-effect and elimination by a proteomics informed-mechanistic PBPK modeling approach
dc.typeThesis
dc.embargo.termsRestrict to UW for 2 years -- then make Open Access
dc.embargo.lift2021-10-04T23:01:01Z


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record